Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasushi Fukuda

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
JTO Clinical and Research Reports|August 9, 2022
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLCHiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, et al.
Investigational New Drugs|December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyHayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
Clinical Lung Cancer|August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2018
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort studyDaichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2018
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab MonotherapyDaichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
JTO Clinical and Research Reports|August 9, 2022
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLCHiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, et al.
Investigational New Drugs|December 1, 2019
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyHayato Kawachi, Motohiro Tamiya, Akihiro Tamiya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, et al.
Clinical Lung Cancer|August 13, 2024
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)Hayato Kawachi, Motohiro Tamiya, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2018
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort studyDaichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2018
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab MonotherapyDaichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, et al.
Therapeutic Advances in Medical Oncology|December 26, 2022
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysisHisashi Tanaka, Shigeru Tanzawa, Toshihiro Misumi, et al.
Pageof 4